Literature DB >> 35608625

Urinary tract infection following intradetrusor onabotulinumtoxina injection for non-neurogenic urgency incontinence: single- vs. multi-dose prophylactic antibiotic treatment regimens.

Tess Crouss1, Youngwu Kim2, Erica Lai3, Vini Chopra3, Matthew Fagan4, Lioudmila Lipetskaia5,6.   

Abstract

INTRODUCTION AND HYPOTHESIS: Urinary tract infection is one of the most common adverse events following onabotulinumtoxinA injection for urgency incontinence. Our hypothesis was that those undergoing injection for urgency incontinence who received more than one dose of prophylactic antibiotics have lower post-procedure urinary tract infection rates compared to those who receive a single dose.
METHODS: We conducted a multi-center retrospective cohort study in females who underwent onabotulinumtoxinA injection for non-neurogenic urgency incontinence to evaluate the effect of single- vs. multi-dose prophylactic antibiotic regimens on the risk of post-procedure urinary tract infection. The primary outcome was the rate of urinary tract infection within 30 days of injection. Our sample size calculation required 136 subjects per group.
RESULTS: Two hundred eighty-one patients were included from four centers. The single-dose cohort included 145 patients (51.6%), and the multi-dose cohort included 136 patients (48.4%). The mean age was 65 years, and patients were primarily Caucasian (81.4%). There was no difference in the rate of urinary tract infections diagnosed within 30 days of injection between the cohorts (single dose 13.8% vs. multi-dose 10.3%, p = 0.369). Those with a positive urine culture within 30 days of injection had a 15.2 times greater odds of having a post-procedure infection than those who did not (95% CI 3.19-72.53). There was no significant difference between the two cohorts in terms of adverse health events following injection.
CONCLUSIONS: In females with non-neurogenic urgency incontinence undergoing onabotulinumtoxinA injection, multi-dose prophylactic antibiotic regimens were not associated with lower post-procedure urinary tract infection rates.
© 2022. The International Urogynecological Association.

Entities:  

Keywords:  antibiotic prophylaxis; botulinum toxin; urgency incontinence; urinary tract infection

Year:  2022        PMID: 35608625     DOI: 10.1007/s00192-022-05236-z

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  6 in total

Review 1.  Clinical practice. Uncomplicated urinary tract infection.

Authors:  Thomas M Hooton
Journal:  N Engl J Med       Date:  2012-03-15       Impact factor: 91.245

2.  A comparison of antibiotic prophylaxis regimens to decrease the risk of post-procedure urinary tract infection after onabotulinum toxin A injection.

Authors:  Jennifer A Bickhaus; Monique Vaughan; Tracy Truong; Yi-Ju Li; Nazema Y Siddiqui
Journal:  Int Urogynecol J       Date:  2020-01-27       Impact factor: 2.894

3.  Best Practice Statement on Urologic Procedures and Antimicrobial Prophylaxis.

Authors:  Deborah J Lightner; Kevin Wymer; Joyce Sanchez; Louis Kavoussi
Journal:  J Urol       Date:  2019-08-23       Impact factor: 7.450

Review 4.  Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.

Authors:  Apostolos Apostolidis; Prokar Dasgupta; Pierre Denys; Sohier Elneil; Clare J Fowler; Antonella Giannantoni; Gilles Karsenty; Heinrich Schulte-Baukloh; Brigitte Schurch; Jean-Jacques Wyndaele
Journal:  Eur Urol       Date:  2008-09-17       Impact factor: 20.096

5.  Refractory idiopathic urge urinary incontinence and botulinum A injection.

Authors:  Linda Brubaker; Holly E Richter; Anthony Visco; Sangeeta Mahajan; Ingrid Nygaard; Thomas M Braun; Matthew D Barber; Shawn Menefee; Joseph Schaffer; Anne M Weber; John Wei
Journal:  J Urol       Date:  2008-05-21       Impact factor: 7.450

6.  OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder.

Authors:  K-D Sievert; C Chapple; S Herschorn; M Joshi; J Zhou; C Nardo; V W Nitti
Journal:  Int J Clin Pract       Date:  2014-04-22       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.